Tumor-associated stress ligand or Phosphoantigen (NKG2D ligand (for stress ligands), pAg (for phosphoantigen))

Tumor-associated stress ligands, principally the NKG2D ligands (such as MICA, MICB, and ULBP1-6 in humans), are cell surface molecules upregulated in response to cellular stress, DNA damage, viral infection, or transformation, and can be recognized by the activating receptor NKG2D on cytotoxic lymphocytes, triggering immune-mediated killing of stressed or malignant cells[2][3][4][5]. Phosphoantigens are small phosphorylated molecules (e.g., IPP, HMBPP), often produced by dysregulated tumor metabolic pathways or pathogens, that are sensed by the γδ T cell receptor, leading to the activation and cytotoxic response of Vγ9Vδ2 T cells[4][1]. Both groups are considered attractive targets for cancer immunotherapy, but are distinct in their molecular structure and immune recognition pathways. Therapeutic strategies targeting these axes include enhancing ligand expression, antibody or CAR-based therapies, and inhibition of ligand shedding, but face safety and selectivity challenges due to potential effects on normal tissue and immune regulation[3][6][5][7].

Other names

NKG2D ligandStress-induced ligandMICA/BMICBULBP1-6pAgIPP (isopentenyl pyrophosphate)HMBPP

Enhancement of immune cell recognition (CAR-T/NKG2D-based immunotherapies, antibody-dependent mechanisms, γδ T cell activation) Induction/augmentation of stress ligand expression (e.g. via chemotherapy, irradiation, or specific drugs)[5][1]